Neuroblastoma stem cells - Mechanisms of chemoresistance and histonedeacetylase inhibitors

Neoplasma

Volumn 59, Issue 6, 2012, Pages 737-746

  Khalil, M A ^a   Hrabeta, J ^a   Cipro, S ^a   Stiborova, M ^b   Vicha, A ^a   Eckschlager, T ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer stem cells; CD133; Histone deacetylase inhibitors; Neuroblastomam

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CD133 ANTIGEN; CD24 ANTIGEN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ETOPOSIDE; GYRASE INHIBITOR; HERMES ANTIGEN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; PACLITAXEL; PROTEIN P53; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; SYNAPTOPHYSIN; TRICHOSTATIN A; VALPROIC ACID; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

APOPTOSIS; CANCER STEM CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; NEUROBLASTOMA; NONHUMAN; REVIEW; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; GENETIC EPIGENESIS; METASTASIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GLYCOPROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PEPTIDES;

EID: 84872685727     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_093     Document Type: Review

References (70)

1. REYA T, MORRISON SJ, CLARKE MF, WEISSMAN IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414, 105-111. http://dx.doi.org/10.1038/35102167
2. BOHL SR, PIRCHER A, HILBE W. Cancer stem cells: characteristics and their potential role for new therapeutic strategies. Onkologie 2011; 34, 269-274. http://dx.doi.org/10.1159/000327815
3. VISVADER JE, LINDEMAN GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8, 755-768. http://dx.doi.org/10.1038/nrc2499
4. LI L, BHATIA R. Stem cell quiescence. Clin Cancer Res 2011; 17, 4936-4941. http://dx.doi.org/10.1158/1078-0432.CCR-10-1499
5. CROKER AK, ALLAN AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008; 12, 374-390. http://dx.doi.org/10.1111/j.1582-4934.2007.00211.x
6. FOLKINS C, SHAKED Y, MAN S, TANG T, LEE CR et al. Glioma tumor stem like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal derived factor 1. Cancer Res 2009; 69, 7243-7251. http://dx.doi.org/10.1158/0008-5472.CAN-09-0167
7. WELTE Y, ADJAYE J, LEHRACH HR, REGENBRECHT CR. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal 2010; 8, 6. http://dx.doi.org/10.1186/1478-811X-8-6
8. RDoyle T, Bryant L, Batinic-Haberle I, Little J, Cuzzocrea S, Masini E, Spasojevic I, Salvemini D, Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance. Neuroscience 164 (2009) 702-710.
9. KRIVTSOV AV, TWOMEY D, FENG Z, STUBBS MC, WANG Y et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442, 818-822. http://dx.doi.org/10.1038/nature04980
10. MORRISON SJ, KIMBLE J. Asymmetric and symmetric stem cell divisions in development and cancer. Nature 2006; 441, 1068-1074. http://dx.doi.org/10.1038/nature04956
11. CICALESE A, BONIZZI G, PASI CE, FARETTA M, RONZONI S et al. The tumor suppressor p53 regulates polarity of self renewing divisions in mammary stem cells. Cell 2009; 138, 1083-1095. http://dx.doi.org/10.1016/j.cell.2009.06.048
12. EYLER CE, RICH JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26, 2839-2845. http://dx.doi.org/10.1200/JCO.2007.15.1829
13. GRIGUER CE, OLIVA CR, GOBIN E, MARCORELLES P, BENOS DJ et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008; 3, e3655. http://dx.doi.org/10.1371/journal.pone.0003655
14. SOEDA A, PARK M, LEE D, MINTZ A, ANDROUTSELLIS-THEOTOKIS A et al. Hypoxia promotes expansion of the CD133 positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28, 3949-3959. http://dx.doi.org/10.1038/onc.2009.252
15. MARIOTTI E, GEMEI M, MIRABELLI P, D'ALESSIO F, DI NOTO R et al. The percentage of CD133+ cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection. BMC Cancer 2010; 10, 120. http://dx.doi.org/10.1186/1471-2407-10-120
16. HIRSCHMANN-JAX C, FOSTER AE, WULF GG, NUCHTERN JG, JAX TW et al. A distinct "side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101, 14228-14233. http://dx.doi.org/10.1073/pnas.0400067101
17. CLARKE MF, DICK JE, DIRKS PB, EAVES CJ, JAMIESON CH et al. Cancer stem cells perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66, 9339-9344.
18. HEMMATI HD, NAKANO I, LAZAREFF JA, MASTER-MAN-SMITH M, GESCHWIND DH et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003; 100, 15178-15183. http://dx.doi.org/10.1073/pnas.2036535100
19. WAN F, ZHANG S, XIE R, GAO B, CAMPOS B et al. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 2010; 20, 877-889.
20. ZHAO L, CHEN X, CAO Y. New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai) 2011; 43, 831-839. http://dx.doi.org/10.1093/abbs/gmr080
21. CHEN H, SHALOM-FEUERSTEIN R, RILEY J, ZHANG SD, TUCCI P et al. miR 7 and miR 214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun 2010; 394, 921-927. http://dx.doi.org/10.1016/j.bbrc.2010.03.076
22. YIN AH, MIRAGLIA S, ZANJANI ED, ALMEIDA-PORADA G, OGAWA M et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90, 5002-5012.
23. DE WYNTER EA, BUCK D, HART C, HEYWOOD R, COUTINHO LH et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long term culture initiating cells, NOD/SCID repopulating cells and dendritic cell progenitors. Stem Cells 1998; 16, 387-396. http://dx.doi.org/10.1002/stem.160387
24. PEICHEV M, NAIYER AJ, PEREIRA D, ZHU Z, LANE WJ et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95, 952-958.
25. UCHIDA N, BUCK DW, HE D, REITSMA MJ, MASEK M et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000; 97, 14720-14725. http://dx.doi.org/10.1073/pnas.97.26.14720
26. CORBEIL D, ROPER K, HELLWIG A, TAVIAN M, MI-RAGLIA S et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275, 5512-5520. http://dx.doi.org/10.1074/jbc.275.8.5512
27. RICHARDSON GD, ROBSON CN, LANG SH, NEAL DE, MAITLAND NJ et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117, 3539-3545. http://dx.doi.org/10.1242/jcs.01222
28. TORRENTE Y, BELICCHI M, SAMPAOLESI M, PISATI F, MEREGALLI M et al. Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest 2004; 114, 182-195.
29. ZHANG H, LI SY. Research progression of CD133 as a marker of cancer stem cells. Chin J Cancer 2010; 29, 243-247. http://dx.doi.org/10.5732/cjc.009.10587
30. SINGH SK, HAWKINS C, CLARKE ID, SQUIRE JA, BAYANI J et al. Identification of human brain tumour initiating cells. Nature 2004; 432, 396-401. http://dx.doi.org/10.1038/ nature03128
31. OLEMPSKA M, EISENACH PA, AMMERPOHL O, UNGEFROREN H, FANDRICH F et al. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007; 6, 92-97.
32. O'Brien Ca, Pollett A, Gallinger S, Dick Je,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445, 106-110. http://dx.doi.org/10.1038/nature05372
33. SUETSUGU A, NAGAKI M, AOKI H, MOTOHASHI T, KUNISADA T et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351, 820-824. http://dx.doi.org/10.1016/j.bbrc.2006.10.128
34. COLLINS AT, BERRY PA, HYDE C, STOWER MJ, MAITLAND NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65, 10946-10951. http://dx.doi.org/10.1158/0008-5472.CAN-05-2018
35. BRUNO S, BUSSOLATI B, GRANGE C, COLLINO F, GRAZIANO ME et al. CD133+ renal progenitor cells contrib NEUROBLASTOMA STEM CELLS 745 ute to tumor angiogenesis. Am J Pathol 2006; 169, 2223-2235. http://dx.doi.org/10.2353/ajpath.2006.060498
36. ZHOU L, WEI X, CHENG L, TIAN J, JIANG JJ. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007; 117, 455-460. http://dx.doi.org/10.1097/01. mlg.0000251586.15299.35
37. MONZANI E, FACCHETTI F, GALMOZZI E, CORSINI E, BENETTI A et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43, 935-946. http://dx.doi.org/10.1016/j.ejca.2007.01.017
38. ERAMO A, LOTTI F, SETTE G, PILOZZI E, BIFFONI M et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15, 504-514. http://dx.doi.org/10.1038/sj.cdd.4402283
39. FERRANDINA G, BONANNO G, PIERELLI L, PERILLO A, PROCOLI A et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008; 18, 506-514. http://dx.doi.org/10.1111/j.1525-1438.2007.01056.x
40. FARGEAS CA, HUTTNER WB, CORBEIL D. Nomenclature of prominin-1 (CD133) splice variants an update. Tissue Antigens 2007; 69, 602-606. http://dx.doi.org/10.1111/j.1399-0039.2007.00825.x
41. CAMPOS B, ZENG L, DAOTRONG PH, ECKSTEIN V, UNTERBERG A, MAIRBAURL H, HEROLD-MENDE C. Expression and regulation of AC133 and CD133 in glioblastoma. Glia 2011; 59, 1974-1986. http://dx.doi.org/10.1002/glia.21239
42. KEYSAR SB, JIMENO A. More than markers: biological significance of cancer stem cell defining molecules. Mol Cancer Ther 2010; 9, 2450-2457. http://dx.doi.org/10.1158/1535-7163.MCT-10-0530
43. CHEN YC, HSU HS, CHEN YW, TSAI TH, HOW CK et al. Oct-4 expression maintained cancer stem like properties in lung cancer derived CD133-positive cells. PLoS One 2008; 3, e2637. http://dx.doi.org/10.1371/journal.pone.0002637
44. NAKAMURA M, KYO S, ZHANG B, ZHANG X, MIZU-MOTO Y et al. Prognostic impact of CD133 expression as a tumor initiating cell marker in endometrial cancer. Hum Pathol 2010; 41, 1516-1529. http://dx.doi.org/10.1016/ j.humpath.2010.05.006
45. KHALIL MA HJ, CIPRO S, VICHA A, ECKSCHLAGER T. (2011) Effect of histone deacetylase inhibitor on expression of CD133 in neuroblastoma cell line, in Biologicke dny Plzen; Plzen, Czech Republic.
46. JAKSCH M, MUNERA J, BAJPAI R, TERSKIKH A, OSHIMA RG. Cell cycle dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008; 68, 7882-7886. http://dx.doi.org/10.1158/0008-5472.CAN-08-0723
47. MARIS JM, HOGARTY MD, BAGATELL R, COHN SL. Neuroblastoma. Lancet 2007; 369, 2106-2120.
48. COHN SL, PEARSON AD, LONDON WB, MONCLAIR T, AMBROS PF et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27, 289-297. http://dx.doi. org/10.1200/JCO.2008.16.6785
49. Mugishima H. Current status of molecular biology and treatment strategy for neuroblastoma. Int J Clin Oncol 2012; May 16. Epub ahead of print. http://dx.doi.org/10.1007/s10147-012-0423-7
50. Hara J. Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol 2012; May 16. Epub ahead of print. http://dx.doi.org/10.1007/s10147-012-0417-5
51. CICCARONE V, SPENGLER BA, MEYERS MB, BIEDLER JL, ROSS RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989; 49, 219-225.
52. WALTON JD, KATTAN DR, THOMAS SK, SPENGLER BA, GUO HF et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004; 6, 838-845. http://dx.doi.org/10.1593/neo.04310
53. TONG QS, ZHENG LD, TANG ST, RUAN QL, LIU Y et al. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008; 4, 58-62. http://dx.doi.org/10.1007/s12519-008-0012-z
54. TAKENOBU H, SHIMOZATO O, NAKAMURA T, OCHIAI H, YAMAGUCHI Y et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011; 30, 97-105. http://dx.doi.org/10.1038/onc.2010.383
55. Kamijo T, Nakagawara A. Molecular and genetic bases of neuroblastoma. Int J Clin Oncol 2012; May 16. Epub ahead of print. http://dx.doi.org/10.1007/s10147-012-0415-7
56. COULON A, FLAHAUT M, MUHLETHALER-MOTTET A, MEIER R, LIBERMAN J et al. Functional sphere profiling reveals the complexity of neuroblastoma tumor initiating cell model. Neoplasia 2011; 13, 991-1004.
57. HANSFORD LM, MCKEE AE, ZHANG L, GEORGE RE, GERSTLE JT et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor initiating cell. Cancer Res 2007; 67, 11234-11243. http://dx.doi.org/10.1158/0008-5472.CAN-07-0718
58. COURNOYER S, NYALENDO C, ADDIOUI A, BELOUNIS A, BEAUNOYER M et al. Genotype analysis of tumor initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 2012; 51, 792-804. http://dx.doi. org/10.1002/gcc.21964
59. Castelo-Branco P, Zhang C, Lipman T, Fujitani M, Hansford L et al. Neural tumor initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011; 17, 111-121. http://dx.doi.org/10.1158/1078-0432.CCR-10-2075
60. SMITH KM, DATTI A, FUJITANI M, GRINSHTEIN N, ZHANG L et al. Selective targeting of neuroblastoma tumour initiating cells by compounds identified in stem cell based small molecule screens. EMBO Mol Med 2010; 2, 371-384.
61. Hirschmann-Jax C, Foster AE, Wulf GG, Good-Ell MA, Brenner MK. A distinct "side population of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4, 203-205. http://dx.doi.org/10.4161/cc.4.2.1406
62. VANGIPURAM SD, WANG ZJ, LYMAN WD. Contributor Resistance of stem like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer 2010; 54, 361-368. http://dx.doi.org/10.1002/pbc.22351
63. OHMICHI M, HAYAKAWA J, TASAKA K, KURACHI H, MURATA Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005; 26, 113-116. http://dx.doi.org/10.1016/j.tips.2005.01.002
64. OWENS DM, KEYSE SM. Differential regulation of MAP kinase signalling by dual specificity protein phosphatases. Oncogene 2007; 26, 3203-3213. http://dx.doi.org/10.1038/sj.onc.1210412
65. NEWTON TC, WOLCOTT K, ROBERTS SS. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl Oncol 2010; 3, 246-251.
66. HREBACKOVA J, HRABETA J, ECKSCHLAGER T. Valproic acid in the complex therapy of malignant tumors. Curr Drug Targets 2010; 11, 361-379. http://dx.doi.org/10.2174/138945010790711923
67. Bug G, Gul H, Schwarz K, Pfeifer H, Kampf-Mann M et al. Valproic acid stimulates proliferation and self renewal of hematopoietic stem cells. Cancer Res 2005; 65, 2537-2541. http://dx.doi.org/10.1158/0008-5472.CAN-04-3011
68. DEBEB BG, XU W, MOK H, LI L, ROBERTSON F et al. Differential radiosensitizing effect of valproic acid in differentiation versus self renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 2010; 76, 889-895. http://dx.doi.org/10.1016/j.ijrobp.2009.09.052
69. BABA T, CONVERY PA, MATSUMURA N, WHITAKER RS, KONDOH E et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28, 209-218. http://dx.doi.org/10.1038/onc.2008.374
70. CIPRO S, HREBACKOVA J, HRABETA J, POLJAKOVA J, ECKSCHLAGER T. Valproic acid overcomes hypoxia induced resistance to apoptosis. Oncol Rep 2011; 27, 1219-1226.